Benefit-risk balance of certain linear gadolinium agents no longer favourable
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed its previous conclusion from March 2017 that there is convincing evidence of gadolinium deposition in brain tissues following use of gadolinium contrast agents.
No specific conditions linked to gadolinium deposition in the brain have been identified, but the clinical consequences are unknown.
More information on the following link:
